$KIDS

Pelizzon David R sold $943K of KIDS (indirect holdings)

Pelizzon David R sold 38,300 indirectly-held shares of ORTHOPEDIATRICS CORP (KIDS) at an average of $24.63 ($24.28–$25.75, $0.94M total) across 3 trades over 2026-08-24 to 2026-08-26.

Original reporting
SEC EDGAR · Pelizzon David R
Published Aug 26, 2026, 10:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KIDS
Neutral
medium confidence
Mentioned
$KIDS
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KIDSNeutralLow
01

Why it matters

The disclosed sale is modest and likely reflects personal financial planning rather than a change in company prospects.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential tax planning or liquidity needs for the insider; not necessarily a negative signal.

Relevance 5/10Novelty 4/10Timing: post‑market filing

Background

Form 4 filings disclose insider transactions; investors monitor large sales for signals.

Company-level read

Ticker impact

$KIDSNeutralMedium confidence
Context

Director and 10% owner sold 38,300 shares for $943K via open-market transactions.

Expected impact

Modest downward pressure; limited impact given the modest size relative to float.

Evidence & confidence

The sale is a routine Form 4 filing; amount is under $1M and represents a small fraction of holdings.

Market effects

Minimal; no broader sector impact.

None.

None.

Counterpoint

The sale could be unrelated to company outlook; may present a buying opportunity if fundamentals remain strong.

Key entities

  • Pelizzon David R

    10% owner of Orthopedics Corp who sold $943K of stock.

  • Orthopedics Corp

    Medical device company trading under ticker KIDS.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KIDSMed

OrthoPediatrics Corp. Q2 2026 Earnings Call Summary

OrthoPediatrics reported Q2 2026 progress toward a “financial inflection point,” citing record adjusted EBITDA margins near 10% and a shift toward positive free cash flow. Trauma and Deformity revenue grew 26% on implant share gains and early 3P Hip deployments. Management expects positive free cash flow in H2 2026 and FCF break-even or better for full-year 2026, with conservative timing assumptions for capital placements and international orders.